Tech Support


This line is for technical support.
For General Enquiries please click General Contact

WEBINAR: Preclinical Obesity Research: Best Practice in Model Selection and Study Design

Thursday September 12, 10:30am ET / 10:30pm ET

Presented by Dr Fred Beasley this webinar will explain how to select the most appropriate models for your preclinical obesity studies, including reviewing polygenic vs monogenic models and recommendations based on drug modes of action. We'll also review best practice in obesity study design to maximize data outcomes.

ON DEMAND WEBINAR: Demonstrating Clinical Relevance in 3D In Vitro Modeling with HUB Organoids

Presented by Dr Sylvia Boj, Hubrecht Organoid Technology this webinar reviews the development and application of HUB Organoids. Explore the many advantages of HUB Organoids within 3D in vitro modeling, including direct clinical relevance and immuno-oncology applications.

NEW WHITE PAPER: How to Assess Immunotherapy Toxicity using NHPs

Learn more about NHPs as a valuable early-stage preclinical platform for non-GLP exploratory toxicology studies. Explore the robust data these studies generate in a rapid, flexible, and cost-effective manner to assess immunotherapy safety and de-risk future clinical trials.

ON DEMAND WEBINAR: Reversing Hypertriglyceridemia and Hepatic Steatosis in Dysmetabolic NHPs with a Controlled-Release Mitochondrial Protonophore (CRMP)

Presented by Dr. Leigh Goedeke of Yale School of Medicine, this webinar details using spontaneous NHP models of NAFLD and metabolic syndrome to assess a controlled-release mitochondrial protonophore (CRMP). Explore proof-of-concept data from these clinically relevant models, supporting the development of novel liver-targeted mitochondrial uncouplers to treat human NASH and T2D.

NEW WHITE PAPER: Optimizing Preclinical Diabetes Studies Using Stress-Free Methods in NHPs

Learn more about novel preclinical techniques for optimizing diabetes studies with spontaneously diabetic NHPs. Explore continuous glucose monitoring and banana tolerance test case studies, and learn how reducing invasiveness and stress leads to improved animal welfare, study data, and clinical outcomes.

Screen Your I/O Agent Efficacy In Vivo with Our 6 Model Tumor Homograft Panel

The tumor homograft MuScreenTM is now available in a smaller panel, covering 6 different indications and with each model harboring clinically-relevant mutations. Screen your I/O agent efficacy in these fully immunocompetent models that have never been passaged in vitro.

NEW WHITE PAPER: How to Improve the Predictive Value of Preclinical Oncology Studies: Imaging Orthotopic Models

Explore the benefits of imaging orthotopic, metastatic models. Read our new White Paper to learn more about key model utilities for studying disease progression and metastasis, and for assessing novel agents for different disease stages.

ON DEMAND WEBINAR: Assessing Immunotherapy Toxicity in NHPs

Presented by Dr Thomas Scullion this webinar focuses on using NHPs for the preclinical assessment of immunotherapy toxicity. Explore how clinical trials are de-risked by evaluating immuno-safety early in drug discovery, and how to incorporate exploratory toxicology NHP studies into your preclinical programs.

WHITE PAPER: Optimizing Translational IBD Capabilities How to Select the Right Preclinical Model

Explore the key features of commonly used preclinical IBD models, including model development and example treatment studies. Learn how to choose the most appropriate model for your drug development program, based on drug target and mechanism of action alongside model disease pathogenesis and clinical relevance.

Download our ADA 2019 Posters

We presented posters on our unique translational NASH model at the ADA Scientific Sessions this year. Download our latest data on NASH induction in the dysmetabolic MS-NASH mouse (formerly FATZO), and accelerated disease induction resulting in a model featuring both severe fibrosis and dysmetabolism.

NEW WHITE PAPER: Key Applications of Syngeneic Models to Maximize I/O Translatability

Learn how to optimize syngeneic translatability through proof of concept and target engagement studies. Read our new White Paper to explore how panels of syngeneic models are used to evaluate new single agent and combination regimens, uncover biomarkers of I/O response, and discover common PD markers for predicting population response.

New Accelerated and Exacerbated Liver Fibrosis Model for NASH Preclinical Studies

Advance your NASH therapeutics with the inherently dysmetabolic, obese, and diabetic MS-NASH mouse (formerly FATZO). Learn more about standard NASH induction on Western diet plus fructose, as well as accelerated disease progression and exacerbated pathology with CCl4 administration. Explore new CCl4 data, including improved lipid profile and NAS score with OCA treatment.


Models of Obesity


CrownBio’s preclinical Translational Technology Platforms provide spontaneous & diet-induced obesity (DIO) models, to support the transition of new agents into the clinic.

Learn More


Oncology Databases


Our unique databases provide a curated source of well-characterized models available to use for drug discovery including PDX models, cell lines, and syngeneic models.

Learn More


Diabetes Models


Models of both Type 1 and Type 2 diabetes, including conventional, as well as unique, highly translatable models for in vivo efficacy studies of antidiabetic agents.

Learn More

Latest from our Blog

August 22, 2019

How Do HUB Organoids Differ from Other Organoid Cultures?

Explore the similarities and differences between the Hubrecht Organoid Technology (HUB) approach and other commonly used methods for establishing organoid cultures.

Read More

August 22, 2019

How Do HUB Organoids Differ from Other Organoid Cultures?

Explore the similarities and differences between the Hubrecht Organoid Technology (HUB) approach...

Read More

August 20, 2019

Circulating Tumor Cells in Preclinical Mouse Models of Metastasis

Explore the utility of preclinical mouse models of metastasis to study circulating tumor cells...

Read More

August 15, 2019

How are Organoids Different from Spheroids?

Explore the similarities and differences between organoids and spheroids - the most commonly...

Read More

August 13, 2019

Continuous Glucose Monitoring in NHP Models

Discover continuous glucose monitoring as an enhanced technique for preclinical blood glucose...

Read More

August 8, 2019

The Development of HUB Organoids

Review the development and use of HUB Organoids, from the first discovery of Lgr5 as an adult...

Read More

Upcoming Events

August 25 - 27, 2019

Cell Symposia - Engineering Organoids and Organs

San Diego, CA

August 28, 2019

CrownBio Inaugural NASH Symposium

Shanghai, China

August 29 - 31, 2019

IGC 2019

Beijing, China

September 12, 2019

Webinar: Preclinical Obesity Research: Best Practice in Model Selection and Study Design

Boston, MA

September 16 - 19, 2019

Discovery on Target

Boston, MA